Inflammatory protein converts glioblastoma cells into most aggressive version

August 29, 2013

A prominent protein activated by inflammation is the key instigator that converts glioblastoma multiforme cells to their most aggressive, untreatable form and promotes resistance to radiation therapy, an international team lead by researchers at The University of Texas MD Anderson Cancer Center reported online today in the journal Cancer Cell.

The discovery by scientists and physicians points to new ways to increase radiation effectiveness and potentially block or reverse progression of , the most common and lethal form of brain tumor.

"We know that the mesenchymal (MES) subgroup of glioblastoma is the most aggressive subgroup clinically," said co-senior author Ken Aldape, M.D., chair and professor of Pathology and Kenneth D. Muller Professor in Tumor Genetics. "This paper shows that the NF-kB pathway causes cells to change to that MES subgroup."

This conversion leads to radiation resistance.

"The pathway we identified serves as an escape mechanism for tumors," said lead author Krishna Bhat, Ph.D., assistant professor of Pathology. "In newly diagnosed patients, even before treatment, these cells already are poised to meet challenges."

NF-?B-driven cell change starts outside the tumor

NF-?B activation is stimulated by inflammation, which occurs in the tumor cell's microenvironment.

"The shift of to a MES type, characterized associated with invasion and new , leads to radiation resistance," said co-senior author Erik Sulman, M.D., Ph.D., assistant professor of Radiation Oncology. "This suggests blocking the inflammatory response to make tumors more sensitive to standard may improve outcomes for patients."

Standard care for glioblastoma is surgery, followed by radiation and chemotherapy and then treatment with temozolomide. An estimated 23,270 people will receive a glioblastoma diagnosis in 2013 and about 14,000 people will die of the disease. Median survival is about one year.

Cell line, mouse model show something missing

"No one really knows how glioblastoma progresses from its early stages because 90-95 percent of cases are diagnosed without prior history of a lower grade glioma," Bhat said. Of these about 50 percent belong to the MES subgroup. A previous study had shown that glioblastomas with a proneural (PN) type, have a much better prognosis. But these less-aggressive tumors tend to recur as the aggressive MES subtype after treatment."

Research at MD Anderson and other institutions identified the two distinct cell types based on genes expressed by each. "We haven't known what makes a cell evolve into the MES subtype," Bhat said.

Bhat took cells from 41 human glioblastoma samples and placed them in cell cultures. Of these, 33 developed into neurospheres, cells that take on stem-cell like characteristics.

Microarray analysis of gene expression in the 17 fastest -expanding cell cultures divided them into two distinct groups: one cluster similar to the MES subtype and the other the PN subtype.

They analyzed expression of four genes commonly expressed by each subtype to see how the cultured cells matched up to their parental tumors.

Cue the surprise

All but two of the cell lines (70 percent) that originated from MES tumors lost their MES characteristics and acquired a PN signature. These results do not match the human experience, Bhat noted. Glioblastoma cells don't retreat from an aggressive to less aggressive state.

Either something in the cell culture system favored enrichment of the PN state, or most glioblastoma neurospheres exist in the less-aggressive PN state, and something in the tumor microenvironment triggers their reversible differentiation into the MES state.

Placing the PN cells cultured from MES tumors in mice did not restore those cells to the parent tumor's more aggressive type.

Different responses to radiation treatment

The researchers implanted glioblastoma sphere culture grafts from MES and PN types in mice and then treated them with radiation.

Those with the PN type had increased survival after treatment compared to controls and had a dramatic accumulation of cells (48 to 78 percent) stuck in a specific phase of the cell cycle caused by irradiation, which lead to massive cell death.

Irradiating MES tumors produced no or minimal survival advantage and the percentages of cells arrested by treatment was reduced to 19-25 percent. The MES cells also showed an enhanced ability to repair damage caused by irradiation.

The Cancer Genome Atlas project for glioblastoma had previously found that genes in the TNF? receptor family and the NF-?B pathway are enriched in MES subclass tumors that also express high levels of the surface receptor CD44.

This team found the exact same pathway had been turned on in the MES cells in their study.

Subsequent experiments found:

  • Treating PN cells with TNF? caused a dramatic increase in CD44 expression. This effect could be reversed by impeding NF-?B.
  • Pretreating PN cells with TNF-alpha before radiation treatment greatly reduced cell damage.
  • NF-?B controls three main transcription factors known to produce the MES cell signature and forces conversion to MES by inducing those factors.

MES cells, CD44 levels, NF-kB activation predict human radiation response

In a cohort of newly diagnosed glioblastoma patients, the team found that those in the MES subgroup, with high levels of CD44 and activated NF-?B had poorer response to radiation and reduced survival.

A separate analysis of PN to MES transition in human tumors showed that regions with higher MES signatures had greater invasion by immune cells called macrophages /microglia – elements of the glioblastoma microenvironment – than did PN areas.

"We know we have to control inflammation in this disease," Bhat said. NF-?B is known to play an important role in promoting inflammation in multiple cell types.

"Surprisingly we found that activation of NF-?B was prevalent in the MES subtype even before surgery and radiation, which in turn can cause inflammation and further activation of NF-?B."

Bhat is investigating downstream targets of NF-?B that promote radiation resistance in glioblastoma.

Inhibitors of NF-?B are in clinical trials for inflammatory and autoimmune diseases, Aldape noted.

"One can imagine a clinical trial in which patients are evaluated for MES status and given an NF-?B inhibitor if they have the MES subtype. You can look at improving response, and also whether you can reverse the MES subtype," Aldape said.

Explore further: Metabolic molecule drives growth of aggressive brain cancer

Related Stories

Metabolic molecule drives growth of aggressive brain cancer

June 13, 2013
(Medical Xpress)—A study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) has identified an abnormal ...

Protein complex linked to cancer growth may also help fight tumors, researchers say

July 22, 2013
Researchers at Moffitt Cancer Center and Tianjin Medical University Cancer Institute and Hospital in China have discovered a gene expression signature that may lead to new immune therapies for lung cancer patients. They found ...

Protein involved in nerve-cell migration implicated in spread of brain cancer

August 7, 2013
The invasion of brain-tumor cells into surrounding tissue requires the same protein molecule that neurons need to migrate into position as they differentiate and mature, according to new research from the University of Illinois ...

Nano drug crosses blood-brain tumor barrier, targets brain tumor cells and blood vessels

July 17, 2013
(Phys.org) —An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a recent study led ...

Cell maturity pathway is deleted or weak in glioblastoma multiforme

August 8, 2013
A program that pushes immature cells to grow up and fulfill their destiny as useful, dedicated cells is short-circuited in the most common and deadly form of brain tumor, scientists at The University of Texas MD Anderson ...

Test helps target glioblastoma patients most likely to benefit from bevacizumab

June 2, 2013
A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin), according to new research from The University of Texas MD Anderson Cancer Center.

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.